Home Cart Sign in  
Chemical Structure| 69-74-9 Chemical Structure| 69-74-9
Chemical Structure| 69-74-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase, with an IC50 of 16 nM for DNA synthesis. It also has antiviral effects against HSV.

Synonyms: Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cytarabine HCl

CAS No. :69-74-9
Formula : C9H14ClN3O5
M.W : 279.68
SMILES Code : O=C1N=C(N)C=CN1[C@@H]2[C@@H]([C@H]([C@H](CO)O2)O)O.[H]Cl
Synonyms :
Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride
MDL No. :MFCD00012839

Safety of Cytarabine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Application In Synthesis of Cytarabine HCl

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 69-74-9 ]

[ 69-74-9 ] Synthesis Path-Downstream   1~36

  • 1
  • [ 108-24-7 ]
  • [ 69-74-9 ]
  • [ 6742-08-1 ]
  • 2
  • [ 69-74-9 ]
  • [ 17676-65-2 ]
  • 3
  • [ 69-74-9 ]
  • [ 219797-98-5 ]
  • [ 186594-89-8 ]
  • 4
  • [ 69-74-9 ]
  • [ 219797-99-6 ]
  • [ 186594-93-4 ]
YieldReaction ConditionsOperation in experiment
is administered intravenously as in Test Procedure A, supra, in conjunction with a chemotherapeutic amount of one of the following antineoplastic agents capable of causing emesis: ... aminoglutethimide, asparaginase, bleomycin, busulfan, cytarabine hydrochloride, daunorubicin, doxorubicin, estramustine phosphate sodium, ...
  • 6
  • [ 75-77-4 ]
  • [ 69-74-9 ]
  • [ 51432-43-0 ]
  • 7
  • [ 69-74-9 ]
  • [ 16640-05-4 ]
  • 8
  • [ 69-74-9 ]
  • N-[1-((2R,3S,4R,5R)-3,4-Bis-trimethylsilanyloxy-5-trimethylsilanyloxymethyl-tetrahydro-furan-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-benzamide [ No CAS ]
  • 9
  • [ 69-74-9 ]
  • [ 6742-07-0 ]
  • 10
  • [ 69-74-9 ]
  • gondoic acid chloride [ No CAS ]
  • CP-4057 [ No CAS ]
  • 11
  • [ 112-77-6 ]
  • [ 69-74-9 ]
  • elacytarabine [ No CAS ]
  • 12
  • [ 69-74-9 ]
  • [ 685111-92-6 ]
YieldReaction ConditionsOperation in experiment
48% Step B: Synthesis of 5'-O-cis-[4-(S)-(pyrid-4-yl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta-D-arabinofuranoside A 1 L jacketed cylindrical reactor was equipped with an overhead stirrer, thermocouple, and two addition funnels (60 ML and 125 ML).The reactor was flushed with nitrogen and charged with DMPU (188 ML, 195.8 g).The stirred liquid was cooled to -16 C. (Julabo F32 chiller/circulator). Diol solution: A 250 ML round bottom flask was equipped with a magnetic stir bar and thermometer.The flask was charged with S-(-)-1-(pyrid-4-yl)-1,3-propanediol (50.0 g), DMPU (62.5 ML, 64.5 g) and pyridine (25.8 g) then placed under a nitrogen atmosphere.The stirred contents were heated to 40 C. (water bath) and stirred at 40-42 C. until all solids were dissolved (10 minutes).The resulting pale orange solution was cooled to 22 C. then charged to the 125 ML addition funnel (volume 127 ML). POCl3 solution: A 125 ML Erlenmeyer flask was charged with acetonitrile (22.9 g) and phosphorus oxychloride (50.0 g).After mixing well, the colorless solution was transferred to the 60 ML addition funnel (volume=60 ML). The two solutions were added simultaneously into the 1 L reactor over 2.6 h, maintaining the temperature below -11 C. After the additions were complete, the viscous pale orange solution was stirred, maintaining the temperature between -11 and -17 C. for 1 h.A sample of the reaction solution was pulled and checked for reaction completion by HPLC (aliquots were hydrolyzed to the cyclic phosphoric acid and then analyzed by HPLC).Cytarabine hydrochloride (60.9 g) was added.The resulting mixture was warmed to 5 C. over 1 h and stirred at 4-6 C. for 87 h.The resulting viscous reaction solution was sampled daily for HPLC analysis.The stirred reaction solution was slowly quenched with NaOH solution (13% wt/vol) at such a rate to maintain the temperature <=20 C., until the PH of the solution reached 5.0 (290 ML of NaOH solution required).dichloromethane (450 ML) was added and the biphasic mixture was stirred at 15-20 C. for 30 minutes.Stirring was stopped and the mixture was allowed to settle for 30 minutes.The lower organic layer was separated.The upper aqueous layer was extracted twice more with dichloromethane (450 ML, 30-minute stir, 30-minute settle) (Note 5): The reactor was fitted with a PH probe and NaOH solution (13% wt/vol) was added over 10 minutes to PH 7.0 (68 ML of NaOH solution required).Cooling (5 C.) was applied to the jacket to keep the temperature below 20 C. The resulting solution was stirred at ambient temperature for 20 h then cooled to 5 C. for 5 h (Note 6).The resulting mixture was filtered and the collected solid was washed with water (2*100 ML) and dried to constant weight (-30 in. Hg, 60 C., 18 h). Recovery=46.6 g of a pale yellow, fine granular solid (48% yield). HPLC for phosphorochloridate synthesis: Column: Zorbax Eclipse XDB-C8, 4.6*250 mm, 5 mum particle size; Solvent A=20 MM:sodium phosphate buffer in 11% acetonitrile/water; solvent B=50% acetonitrile in de-ionized water (gradient 100% A to 100% B in 15 minutes); flow rate=1.0 ML/min; injection volume=10 muL UV detection at 250 nm, column temperature=30 C. r.t.=4.3 min. HPLC for 5'-O-cis-[4-(S)-(pyrid-4-yl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta-D-arabinofuranoside: Columns: Inertsil ODS-3, 4.6*150 mm, 3 mum particle size; Solvent A=20 MM ammonium phosphate buffer in 5%. acetonitrile/water; solvent B=acetonitrile (gradient (time in minutes/% B in A%): 0/0, 30/10, 40/40, 40.1/0 50/0); flow rate=1.0 ML/min; injection volume=50 muL UV detection at 210 nm, column temperature=30 C.+-5 C. r.t.=15.7 min
  • 13
  • (4S)-(-)-trans-(4-pyridyl)-2-chloro-2-oxo-1,3,2-dioxaphosphorinane [ No CAS ]
  • [ 69-74-9 ]
  • [ 685111-92-6 ]
YieldReaction ConditionsOperation in experiment
26% Method A An oven- dried 250 ML round bottom flask equipped with a magnetic stir bar was charged with 3.35 g of cytarabine-HCl and 6.0 ML of DMPU. Into this flask the reaction mixture from example 12 was filtered directly and the DABCO-HCl salt was washed quickly with acetonitrile (1*15 ML).Volatiles were removed on a rotary-evaporator under aspirator vacuum (bath temp <35 C.).The residual oil was briefly kept under high vacuum and stirred at room temperature for 48 h.The reaction mixture was treated with 100 ML of MeOH and stirred for 2 hours at room temperature.The PH of the reaction mixture was adjusted to 7.0 using 25 wt % NaOMe solution in methanol (approximately 13 ML were required).At this stage the reaction mixture was turbid. HPLC was run to insure integrity of the reaction profile.The reaction mixture was evaporated to dryness and the residue was stirred with 50 ML of dichloromethane for 30 minutes at room temperature.The precipitate was collected by filtration, washed with methylene chloride (1*20 ML) and transferred back to the flask, stirred again with 50 ML of dichloromethane for 15 minutes and filtered.The solid was stirred with 200 ML of ethanol for 1-2 hours, filtered and washed with ethanol (2*10 ML).The filtrate was evaporated to dryness to give 4.90 g of a white solid.This solid was dissolved in 10 ML of H2O and stirred at room temperature overnight to give a solid which was collected by filtration, washed with water (2*3 ML) and dried in a vacuum oven to give compound 9, 1.38 g, (26%).
  • 14
  • [ 147-94-4 ]
  • [ 69-74-9 ]
YieldReaction ConditionsOperation in experiment
96% With hydrogenchloride; In methanol; at 2 - 25℃; for 4h; An oven- dried 250 mL round bottom flask equipped with a magnetic stir bar was charged with 3.35 g of cytarabine-HCl and 6.0 mL of DMPU. Into this flask the reaction mixture from example 12 was filtered directly and the DABCO-HCl salt was washed quickly with acetonitrile (1×15 mL). Volatiles were removed on a rotary-evaporator under aspirator vacuum (bath temp <35 C.). The residual oil was briefly kept under high vacuum and stirred at room temperature for 48 h. The reaction mixture was treated with 100 mL of MeOH and stirred for 2 hours at room temperature. The pH of the reaction mixture was adjusted to 7.0 using 25 wt % NaOMe solution in methanol (approximately 13 mL were required). At this stage the reaction mixture was turbid. HPLC was run to insure integrity of the reaction profile. The reaction mixture was evaporated to dryness and the residue was stirred with 50 mL of dichloromethane for 30 minutes at room temperature. The precipitate was collected by filtration, washed with methylene chloride (1×20 mL) and transferred back to the flask, stirred again with 50 mL of dichloromethane for 15 minutes and filtered. The solid was stirred with 200 mL of ethanol for 1-2 hours, filtered and washed with ethanol (2×10 mL). The filtrate was evaporated to dryness to give 4.90 g of a white solid. This solid was dissolved in 10 mL of H2O and stirred at room temperature overnight to give a solid which was collected by filtration, washed with water (2×3 mL) and dried in a vacuum oven to give compound 9, 1.38 g, (26%).
With hydrogenchloride; In diethyl ether; A suspension of cytarabin hydrochloric salt (prepared from cytarabin and 1M HC1 in diethyl ether) (839 mg, 3.0 mmol) in DMA (10 ml) was added to the acid chloride of monomethyl azelaic acid (761 mg, 3.45 mmol) in DMA (2 ml) and the mixture stirred at room temperature overnight. NEt3 was added to the reaction mixture (303 mg, 3.0 mmol) and the mixture evaporated in vacuo. The residue was transferred to a flash column with silica gel and separated with (CH2C12/MEOH 10 : 1) as eluent system to leave the product as a white solid. Yield: 278 mg, (21.6 %). 1H-NMR (DMSO-D6, 300 MHz): 5 7.47 (d, 1 H), 7.10 (br d, 2 H), 6.09 (d, 1 H), 5.67 (d, 1 H), 5.60-5. 56 (m, 2 H), 4.33-3. 88 (m, 2 H), 3.98-3. 96 (m, 1 H), 3.94-3. 88 (m, 2 H), 3.57 (s, 3 H), 3.33 (br s, 1 H), 2.34-2. 25 (m, 4 H), 1.54-1. 47 (m, 4 H), 1.22 (br s, 6 H). 3C-NMR (DMSO-D6, 75 MHz) : 8 173.3, 172.8, 165.5, 155.0, 142.8, 92.5, 86.1, 81.7, 76.7, 74.2, 63.6, 51.1, 45.2, 33.5, 33.1, 28.2, 28.1, 24.3, 8.4.
  • 15
  • [ 56555-02-3 ]
  • [ 69-74-9 ]
  • [ 848046-38-8 ]
YieldReaction ConditionsOperation in experiment
21.6% A suspension of cytarabin hydrochloric salt (prepared from cytarabin and 1M HC1 in diethyl ether) (839 mg, 3.0 mmol) in DMA (10 ml) was added to the acid chloride of monomethyl azelaic acid (761 mg, 3.45 mmol) in DMA (2 ml) and the mixture stirred at room temperature overnight. NEt3 was added to the reaction mixture (303 mg, 3.0 mmol) and the mixture evaporated in vacuo. The residue was transferred to a flash column with silica gel and separated with (CH2C12/MEOH 10 : 1) as eluent system to leave the product as a white solid. Yield: 278 mg, (21.6 %). 1H-NMR (DMSO-D6, 300 MHz): 5 7.47 (d, 1 H), 7.10 (br d, 2 H), 6.09 (d, 1 H), 5.67 (d, 1 H), 5.60-5. 56 (m, 2 H), 4.33-3. 88 (m, 2 H), 3.98-3. 96 (m, 1 H), 3.94-3. 88 (m, 2 H), 3.57 (s, 3 H), 3.33 (br s, 1 H), 2.34-2. 25 (m, 4 H), 1.54-1. 47 (m, 4 H), 1.22 (br s, 6 H). 3C-NMR (DMSO-D6, 75 MHz) : 8 173.3, 172.8, 165.5, 155.0, 142.8, 92.5, 86.1, 81.7, 76.7, 74.2, 63.6, 51.1, 45.2, 33.5, 33.1, 28.2, 28.1, 24.3, 8.4.
  • 16
  • mono (2,2,2-trichloroethyl) azelaoyl chloride [ No CAS ]
  • [ 69-74-9 ]
  • [ 879015-37-9 ]
YieldReaction ConditionsOperation in experiment
56.7% In DMA; at 20℃; Mono (2, 2, 2-trichloroethyl) ester of azelaic acid (2.41g, 7.5 mmol) in CH2Cl2 (75 ml) was added to SOCl2 (3.58 g, 30.0 mmol) and stirred under reflux for 3 hours. The reaction mixture was concentrated in vacuo and the mono [2, 2, 2-trichloroethyl) azelaoyl chloride used in the next step without any further purification. A suspension of Ara-C HCl (1.01 g, 3.6 mmol) in DMA (15 ml) was added to the acid chloride (1.41 g, 4.2 mmol) in DMA (5 ml) and stirred at room temperature overnight. The reaction mixture was evaporated in vacuo and the residue added to EtOAc (40 ml) and brine (20 ml) . The organic layer was separated, dried over Na2SO4, filtered and evaporated in vacuo to give the crude product as an oil. The oil was purified on a column of silica gel with MeOH (5-30 %) in CH2Cl2 as the eluent system to give 5"- O- [ (2, 2, 2-trichloroethyl) azelaoyl] 1-beta-D- arabinofuranosyl-cytosine as a white solid (1.10 g, 56.7%) .1H-NMR (DMSO-d6) : delta 7.49 (d, 1 H) , 7.10 (br d, 2 H), 6.10 (d, 1 H), 5.69 (d, 1 H), 5.58 (t, 2 H), 4.89 (s, 2 H), 4.37-4.15 (m, 2 H), 4.01-3.89 (m, 3 H), 3.36 (br s, 1 H), 2.47 (t, 2 H), 2.34 (t, 2 H), 1.65-1.53 (ralpha, 4 H), 1.28 (br s, 6 H)13C-NMR (DMSO-d6) : delta 172.7, 171.4, 165.5, 155.0, 142.8, 95.3, 92.5, 86.1, 81.7, 76.7, 74.2, 72.9, 63.7, 55.6, 33.3, 33.1, 28.2, 28.1, 24.3, 24.1MS (ES) : 566.0 {M + Na] +
  • 17
  • [ 69-74-9 ]
  • [ 501-53-1 ]
  • [ 170935-63-4 ]
YieldReaction ConditionsOperation in experiment
15% With potassium hydrogencarbonate; In water; ethyl acetate; at 80℃; for 16h; benzyl 1-(3, 4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl)-2-oxo- 1, 2- dihydropyrimidin-4-ylcarbamate (58) SU0044-3a/02; Cytarabine.HCI (200 mg, 0.72 mmol) was dissolved in H2O (2 mL). To this was added KHCO3 (72 mg, 0.72 mmol) and benzyl carbonochloridate (107 mul_, 0.72 mmol), predissolved in ethyl acetate (5 mL). The mixture was stirred at 80 0C for 16 h. The solvent was evaporated off in vacuo and the product was purified by flash chromatography, eluting with 3% MeOH in ethyl acetate to give 58 (40 mg, 15%) as an oil. m/z = 378.13 (M+H).
  • 18
  • [ 69-74-9 ]
  • [ 39552-77-7 ]
  • naphthalen-1-ylmethyl 1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium hydrogencarbonate; In N,N-dimethyl acetamide; at 20℃; for 16h; naphthalen-1-ylmethyl 1-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2- oxo-1,2-dihydropyrimidin-4-ylcarbamate (55) SU001-03; Naphthalen-1-ylmethanol (3.0 g, 19.0 mmol) was added in one portion to COCI2 (13.3 ml_, as 20% solution of COCI2 in toluene) in THF (30 mL). The reaction was stirred at room temperature for 2 h. Excess COCI2 and THF was removed under reduced pressure. The solid residue was dissolved in hot hexane and filtered. The hexane was then slowly evaporated off in vacuo to obtain the chloroformate intermediate 54 as a white solid. This was used straight away in the following step. 54 (330 mg, 1.5 mmol) and KHCO3 (252 mg, 2.52 mmol) were added to a solution of cytarabine.HCI (243 mg, 0.87 mmol) in dimethyl acetamide (5 mL), and the mixture was stirred for 16 h at room temperature. The solvent was evaporated off in vacuo and the product was purified by flash chromatography, eluting with a gradient of 2.5% -12% MeOH in DCM to obtain 55 (38 mg, 10%) as a white solid, m/z = 428.15 (M+H).
  • 19
  • [ 1257411-78-1 ]
  • [ 69-74-9 ]
  • [ 1257411-79-2 ]
  • 20
  • [ 1257411-82-7 ]
  • [ 69-74-9 ]
  • [ 1257411-83-8 ]
  • 21
  • [ 24424-99-5 ]
  • [ 69-74-9 ]
  • tert-butyl 1-((2R,3S,4R,5R)-3,4-bis(tert-butoxycarbonyloxy)-5-((tert-butoxycarbonyloxy)-methyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-ylcarbamate [ No CAS ]
  • [ 1257411-75-8 ]
  • 22
  • [ 24424-99-5 ]
  • [ 69-74-9 ]
  • [ 1257411-76-9 ]
  • [ 1257411-77-0 ]
  • 23
  • [ 69-74-9 ]
  • [ 1257411-77-0 ]
  • 24
  • [ 69-74-9 ]
  • [ 1257411-84-9 ]
  • 25
  • [ 69-74-9 ]
  • [ 82626-74-2 ]
  • [ 1257411-86-1 ]
  • 26
  • [ 69-74-9 ]
  • [ 573704-25-3 ]
  • [ 1257411-85-0 ]
  • 27
  • [ 69-74-9 ]
  • [ 362512-44-5 ]
  • [ 1257411-84-9 ]
  • 28
  • [ 79-03-8 ]
  • [ 69-74-9 ]
  • [ 881848-60-8 ]
  • 29
  • [ 69-74-9 ]
  • [ 142-61-0 ]
  • C15H23N3O6 [ No CAS ]
  • 30
  • [ 69-74-9 ]
  • [ 112-13-0 ]
  • [ 58611-44-2 ]
  • 31
  • [ 69-74-9 ]
  • [ 75-36-5 ]
  • [ 31088-09-2 ]
  • 32
  • [ 69-74-9 ]
  • [ 141-75-3 ]
  • [ 917898-23-8 ]
  • 33
  • [ 69-74-9 ]
  • [ 111-64-8 ]
  • [ 31088-08-1 ]
  • 34
  • [ 69-74-9 ]
  • [ 577-11-7 ]
  • C9H13N3O5*C20H38O7S [ No CAS ]
YieldReaction ConditionsOperation in experiment
In water; at 70℃; for 1h; The reaction scheme between <strong>[69-74-9]cytarabine hydrochloride</strong> and AOT is shown in Scheme 1. For the synthesis of cytarabine-AOT amphiphile, <strong>[69-74-9]cytarabine hydrochloride</strong> and AOT were separately dissolved in water with the equal molar amount. Then AOT solution was slowly added to the <strong>[69-74-9]cytarabine hydrochloride</strong> solution. Subsequently, the resulting mixture was allowed to reaction for 1 h under gently stirring at 70 C. The solution was then lyophilized. When the freeze-drying process was complete, the vials were immediately filled with anhydrous acetone to precipitate NaCl, which was further centrifuged at 10,000 rpm for 10 min. Finally, the supernatant was evaporated to dryness at 50 C under vacuum in a rotary evaporator. To fully remove the solvent residues, the product was stored under vacuum 24 h. The desirable amount of cytarabine-AOT was dissolved in water at room temperature and the bluish vesicular dispersions were formed in 2 h. The preparation process of cytarabine-AOT amphiphiles and the self-assembled vesicles are shown in Scheme 2. In the cytarabine-AOT amphiphiles, the active ingredient is cytarabine cation.
  • 35
  • [ 10212-25-6 ]
  • [ 69-74-9 ]
YieldReaction ConditionsOperation in experiment
62.4% With ammonia; In water; at 80℃; for 0.5h; In a three-necked flask, 79 g of cyclocytidine hydrochloride and 355 ml of water were added.After stirring and dispersing evenly,Add 61g of concentrated ammonia water,Then turn on the heating,The reaction was carried out at 80 C for 0.5 h; the solvent was distilled off under reduced pressure.When it is basically evaporated to dryness, it is heated and stirred by adding 250 ml of methanol.When all is dissolved,Add 142 ml of 4M hydrochloric acid methanol,After the addition was completed, the mixture was stirred at room temperature for 1 h;Isopropanol rinsed twice,Each time the amount of isopropyl alcohol is 25ml,The filter cake was air-dried at 50 C for 16 h; the white solid powder was obtained.Weighing 72.9g,That is, crude cytarabine hydrochloride,Yield 87%,Calculated as cyclocytidine hydrochloride; purity was 99.5%.(4) Purification of cytarabine hydrochlorideAdd 72.9g crude cytarabine hydrochloride and 73ml water to the three-necked bottle.Heat to dissolve, filter,The filtrate was stirred at 40 C.Drip 360ml of isopropanol,After the addition is completed,Stir at room temperature for 0.5 h;Rinse twice with isopropyl alcohol,Each time the amount of isopropyl alcohol is 25ml,The filter cake was dried by blowing at 50 C for 16 hours; the white crystalline powder was obtained.Weighing 45.5g, namely cytarabine hydrochloride,The yield is 62.4%,Based on the crude cytarabine hydrochloride; the total yield of the route is 39.5%.Calculated as cytidine; purity was 99.91%.
  • 36
  • 2-(pyridin-2-yldisulfaneyl)ethyl 1H-1,2,4-triazole-1-carboxylate [ No CAS ]
  • [ 69-74-9 ]
  • 2-(pyridin-2-yldisulfaneyl)ethyl (1-((3S,4S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate [ No CAS ]
YieldReaction ConditionsOperation in experiment
63% With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 2h; A mixture of <strong>[69-74-9]cytarabine hydrochloride</strong> (10 mg, 0.036 mmol, 1 eq.), compound 3 (15.1 mg, 5.4 mmol, 1.5 eq.) and DIEA (19 pL, 0.11 mmol, 3 eq.) were dissolved in methylene chloride (5mL) and stirred at room temperature for 2 hour. The solvent was removed in vacuum and the crude product was purified by using prep HPLC and eluted with 30% to 90% methanol, to obtain compound 4 as white solid (Yield 63%). 'H NMR (400 MHz, DMSO-d6): d 9.5l(s, 1H, N-H), 8.84 (s, 1H, Ar-H), 8.46 (d, J= 5.6 Hz, 1H, Ar-H), 7.79-7.87 (m, 2H, Ar-H), 7.75 (d, J= 8.1 Hz, 1H, Ar-H), 7.21-7.29 (m, 1H, Ar-H), 6.01-6.10 (m, 2H, CH), 4.25 (m, 5H, CH, OH), 4.00-4.09 (m, 2H, CH), 3.15 (t, J= 6.0 Hz, 2H,CH2), 2.54 (s, 1H, OH).
 

Historical Records

Categories